AVITA Medical, Inc. (RCEL) is a Healthcare stock trading at $4.01 (as of 2026-06-18), with a market capitalization of $133.26M and a trailing P/E of -2.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
AVITA Medical, Inc. develops regenerative tissue products in the United States, Australia, and the United Kingdom, using technology based on a patient’s own skin to create treatment solutions. Its RECELL System device is used by healthcare professionals to prepare a cell suspension from a small skin sample for treating acute thermal burns in patients 18 and older, and the company has research collaborations including the University of Colorado and Houston Methodist.